|
| Non-de novo metastatic | De Novo metastatic N = 415 | p value | |
| Fast relapsea N = 250 | Slow relapseb N = 594 | |||
| Mean age (95% CI) | 74.5 (73.8 - 75.3) | 76.1 (75.6 - 76.6) | 74.7 (74.1 - 75.3) | <0.0001 |
| Initial stage at diagnosis, % |
|
|
|
|
| Stage I | 27 | 35 | - | <0.0001 |
| Stage II | 42 | 43 | - |
|
| Stage III | 32 | 22 | - |
|
| Stage IV | - | - | 100 |
|
| Radiotherapy, % |
|
|
|
|
| No | 28 | 25 | 50 | <0.0001 |
| Yes | 72 | 75 | 50 |
|
| Surgery, % |
|
|
|
|
| No | 8 | 6 | 51 | <0.0001 |
| Yes | 92 | 94 | 49 |
|
| Chemotherapy, % |
|
|
|
|
| Capecitabine | 5 | 11 | 13 | 0.0086 |
| Carboplatin | 10 | 13 | 11 | 0.4948 |
| Cyclophosphamide | 25 | 32 | 26 | 0.0397 |
| Docetaxel | 23 | 21 | 26 | 0.2359 |
| Doxorubicin | 16 | 23 | 19 | 0.0611 |
| Paclitaxel | 18 | 24 | 27 | 0.0217 |
| Median (IQR) duration of chemo, days | 58 (30 - 128) | 116 (72 - 164) | 102 (50 - 149) | <0.0001 |
| Median (95% CI) OS, months | 12.1 (9.4 - 16.0) | 19.9 (16.4 - 24.6) | 7.8 (6.7 - 8.9) | <0.0001 |